Antibody alarm call rouses immune response to cancer.
Erika Check
EC
Hayden
D000906:Antibodies / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D016233:Immunotherapy, Active / Q000009:adverse effects / Q000379:methods*; D000074324:Ipilimumab; D008024:Ligands; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D014020:Tissue Extracts / Q000276:immunology / Q000627:therapeutic use
D000906:Antibodies; D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D000074324:Ipilimumab; D008024:Ligands; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D014020:Tissue Extracts; C511774:sipuleucel-T